0001193125-11-138658.txt : 20110513 0001193125-11-138658.hdr.sgml : 20110513 20110513093946 ACCESSION NUMBER: 0001193125-11-138658 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20110512 FILED AS OF DATE: 20110513 DATE AS OF CHANGE: 20110513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AEGON NV CENTRAL INDEX KEY: 0000769218 STANDARD INDUSTRIAL CLASSIFICATION: LIFE INSURANCE [6311] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10882 FILM NUMBER: 11838059 BUSINESS ADDRESS: STREET 1: AEGONPLEIN 50 STREET 2: PO BOX 85 CITY: THE HAGUE STATE: P7 ZIP: 2501 CB BUSINESS PHONE: 011-31-70-344-7308 MAIL ADDRESS: STREET 1: AEGONPLEIN 50 STREET 2: PO BOX 85 CITY: THE HAGUE STATE: P7 ZIP: 2501 CB 6-K 1 d6k.htm FORM 6-K FORM 6-K

Securities and Exchange Commission

Washington, D.C. 20549

Form 6-K

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d/16 of

the Securities Exchange Act of 1934

May 2011

AEGON N.V.

AEGONplein 50

2591 TV THE HAGUE

The Netherlands


AEGON’s press release, dated May 12, 2011, is included as appendix and incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   

AEGON N.V.

    (Registrant)

Date: May 13, 2011

  By  

/s/ E. Lagendijk

    E. Lagendijk
    Executive Vice President and
    General Counsel
EX-99.1 2 dex991.htm EXHIBIT 99.1 EXHIBIT 99.1
       
PRESS RELEASE    LOGO    MAY 12, 2011    LOGO

Summary of Annual General Meeting of Shareholders

 

o All resolutions of the Annual General Meeting of Shareholders adopted
o Mr. Alex Wynaendts reappointed to the Executive Board
o Mr. Antony Burgmans, Mrs. Karla Peijs and Mr. Leo van Wijk reappointed to the Supervisory Board
o No dividend for 2010

Resolutions of the 2011 Annual General Meeting of Shareholders*

The decisions made by the shareholders at the 2011 Annual General Meeting of Shareholders (AGM) include the following:

Reappointments

Mr. Alex Wynaendts was reappointed as a member of the Executive Board for another term of four years as of May 12, 2011.

Mr. Antony Burgmans, Mrs. Karla Peijs and Mr. Leo van Wijk were reappointed as members of the Supervisory Board for another term of four years as of May 12, 2011.

Dividend

AEGON will not pay a dividend on its common shares over 2010.

Annual accounts

The AGM adopted the annual accounts for the financial year 2010 and the members of the Executive Board and Supervisory Board were released from liability for their duties.

Authorizations Executive Board

The AGM authorized the Executive Board to issue common shares, to restrict/exclude pre-emptive rights upon issuing common shares, to issue common shares under incentive plans and to acquire shares in the company.

Appointment independent auditor

Ernst & Young was appointed as the independent auditor for the Annual Accounts 2011.

Adjustments Executive Board Remuneration Policy adopted

The adjustments to the Remuneration Policy for the members of the Executive Board were adopted. The adjustments will take effect from January 1, 2011.

*The full details of the resolutions approved during the shareholders’ meeting may be found in the 2011 AGM section at AEGON’s corporate website: http://www.aegon.com/Home/Investors/Publications/AGM/


 

LOGO

 

 

 

About AEGON

As an international life insurance, pension and asset management company based in The Hague, AEGON has businesses in over twenty markets in the Americas, Europe and Asia. AEGON companies employ approximately 27,500 people and have some 40 million customers across the globe.

 

  

Contact information

 

Media relations:

Greg Tucker

+31(0)70 344 8956

gcc-ir@aegon.com

 

Investor relations:

Willem van den Berg

+31 (0)70 344 8305

877 548 9668 – toll free USA only

ir@aegon.com

 

www.aegon.com

 

Key figures - EUR    Q1 2011      Full year 2010     
Underlying earnings before tax    414 million      1.8 billion     
New life sales    501 million      2.1 billion     
Gross deposits    7.4 billion      33 billion     

Revenue-generating investments

(end of period)

   400 billion      413 billion     
          
          

 

Forward-looking statements

The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, is confident, will, and similar expressions as they relate to our company. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. We undertake no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:

 

  o Changes in general economic conditions, particularly in the United States, the Netherlands and the United Kingdom;  
  o Changes in the performance of financial markets, including emerging markets, such as with regard to:  
  - The frequency and severity of defaults by issuers in our fixed income investment portfolios; and  
  - The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities we hold;  
  o The frequency and severity of insured loss events;  
  o Changes affecting mortality, morbidity, persistence and other factors that may impact the profitability of our insurance products;  
  o Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;  
  o Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates;  
  o Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets;  
  o Changes in laws and regulations, particularly those affecting our operations, the products we sell, and the attractiveness of certain products to our consumers;  
  o Regulatory changes relating to the insurance industry in the jurisdictions in which we operate;  
  o Acts of God, acts of terrorism, acts of war and pandemics;  
  o Changes in the policies of central banks and/or governments;  
  o Lowering of one or more of our debt ratings issued by recognized rating organizations and the adverse impact such action may have on our ability to raise capital and on our liquidity and financial condition;  
  o Lowering of one or more of insurer financial strength ratings of our insurance subsidiaries and the adverse impact such action may have on the premium writings, policy retention, profitability of its insurance subsidiaries and liquidity;  
  o The effect of the European Union’s Solvency II requirements and other regulations in other jurisdictions affecting the capital we are required to maintain;  
  o Litigation or regulatory action that could require us to pay significant damages or change the way we do business;  
  o Customer responsiveness to both new products and distribution channels;  
  o Competitive, legal, regulatory, or tax changes that affect the distribution cost of or demand for our products;  
  o The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including our ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions;  
  o Our failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving initiatives;  
  o Our inability to obtain consent from the Dutch Central Bank to repurchase our Core Capital Securities; and  
  o The non-fulfillment of the conditions precedent underlying the agreement to divest Transamerica Reinsurance.  

Further details of potential risks and uncertainties affecting the company are described in the company’s filings with Euronext Amsterdam and the US Securities and Exchange Commission, including the Annual Report on Form 20-F. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, the company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

GRAPHIC 3 g188295g18j86.jpg GRAPHIC begin 644 g188295g18j86.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`%@`"`P$1``(1`0,1`?_$`%X```,````````````` M```````("@$``P````````````````````<($``!`P4````````````````` MYABHU0<(66D1``$$`P$```````````````#CI19FT@16!__:``P#`0`"$0,1 M`#\`H3:3R*GRI"F)S>F5,G&%4EX4!I/(J?*D">\PX[.!__]D_ ` end GRAPHIC 4 g188295g56g81.jpg GRAPHIC begin 644 g188295g56g81.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S`%(#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#U#4?$^C:5 MN%S?1^8O_+-#O;/I@?UKE-1^)K$E-,L>.TEP?_91_C61X^TI=.\0&>-<1WBF M7_@6?F_I^=MSPL3C:\9N"TL=3IUYXF\6ZD4BU$H8`)<$E(Q@ MC`PO7\:Z7Q+\2-/\+ZO%I-WI]]C&YT7P3-J-K'(U MU>W*K'L4DA%/MVX;\ZI^*X]?;XHZ)JOAZ*W-S>::PA%UD)P&+@^X#"N3&;^Z MK):';@=O>;^(]CXAU9=/BTG5+1F1G\VZA"(`HSR M+2](U+5H+8XFN;:/,:^X/I[G%&LW/C*+X=>(Y/$*644XM\0&R)^X>'SD^AIW MA&YET'X2Z9=Z%I!U.=T#/!$VTNS,=Y)P>G]*X#T#I]"\6:-XBT1M8L;H"VC! M\[S?E,.!DAAVXYKE9OC'IF^26ST35KS3X6Q)?10?NQZGGM]<5R6IZ['=_#_Q M9!8>'$T*>&YA6]2.3>6+.=V>!C!&,=.:]8\*6UG#X/TN"T1#;&SCP`,ALJ"2 M?J2(S[8?!'C:SM3G3X-6B^SX^Z/WC#C\`M:#W$W@32-5\-WD MCMI6MZ6USI\K<[)3'RGXGC_OGUH`]BT_Q%:ZCIUM?112K'^(FG?:_#XNE7+VCA_^`G@_P!#^%>5U[Q> M6R7ME-:RC*3(4;Z$8KSG2?AU<7J^==7\<4.2,1*68X^N`/UKU\%B(PI-3>QX MV.PTIU4X+?\`0IR^-[VWL;.ST@&RBMHMC;@KESZ\CC_Z]:]O%K/C3P];W-KJ M7V#6-/N6,5X800492",8QR#^E='IO@K0]-(<6OVB0?QSG?\`IT_2MBXM(+JR MELY4_$N:I+Y'%Z9X3\:"_0:YXKB MU+36#)5?"GPS30K36['4KT M:E:ZL%#[E*OP&R2<]"."/.R-0BY.3@#`YH`P](\-S:;HUC8/<([ 26MO'"6"D!BJ@9_2BN@HH`__9 ` end